BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Non-small cell lung cancer clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for non-small cell lung cancer: 1018 (388 sponsors; 121 newly posted in the last 180 days, 53 stopped in the last 180 days; 40 new-entrant sponsors). Momentum score 14.9, rank 43 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 5, Phase 1 256, Phase 2 400, Phase 3 244, Phase 4 7, N/A 88.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
AstraZeneca AZN85P3 31, P4 1, P2 25, NA 19, P1 958
Merck Sharp & Dohme LLC MRK29P3 19, NA 1, P2 913
Sichuan Baili Pharmaceutical Co., Ltd.26P2 10, P3 10, P1 655
Bristol-Myers Squibb BMY26P3 8, P2 9, NA 5, P1 443
Hoffmann-La Roche11P3 8, NA 1, P2 201
Akeso13P3 7, P2 622
Eli Lilly and Company LLY19P1 9, P2 3, P3 6, P4 123
AbbVie ABBV16P3 6, P2 3, P1 731
Janssen Research & Development, LLC16NA 1, P2 8, P3 5, P1 205
Daiichi Sankyo15P2 5, P3 5, P1 4, NA 121
Jiangsu Hansoh Pharmaceutical Co., Ltd.15P3 5, P1 9, P2 133
Suzhou Suncadia Biopharmaceuticals Co., Ltd.10P2 5, P3 541
Amgen AMGN9P3 5, P1 2, P2 202
Qilu Pharmaceutical Co., Ltd.8P3 5, P2 1, P1 203
Shanghai JMT-Bio Inc.8P2 3, P3 501
CSPC Megalith Biopharmaceutical Co.,Ltd.6P3 5, P2 122
Pfizer PFE22P1 8, P2 4, P3 4, P4 3, NA 331
Shanghai Henlius Biotech11P2 5, P1 2, P3 412
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY11P2 7, P3 432
Allist Pharmaceuticals, Inc.9P3 4, P2 4, P1 103
Mirati Therapeutics Inc.5P2 2, P3 300
Changchun GeneScience Pharmaceutical Co., Ltd.3P3 301
Summit Therapeutics SMMT3P3 300
Regeneron Pharmaceuticals REGN10P2 6, P3 2, NA 201
Revolution Medicines, Inc. RVMD9P2 4, P1 3, P3 212

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P2Genentech, Inc.NCT04302025 A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung Canceractive not recruiting99
2026-11-30 est.P2Innovent Biologics (Suzhou) Co. Ltd.NCT07122687 IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell LungResectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancerrecruiting170
2026-11-30 est.P2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07256509 A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous NoNon-Small Cell Lung Cancernot yet recruiting120
2026-12 est.P3Allist Pharmaceuticals, Inc.NCT04853342 To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small CNon-small Cell Lung Carcinomarecruiting318
2026-12 est.P1/P23D Medicines (Sichuan) Co., Ltd.NCT05024214 Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsSolid Tumors; Non-small Cell Lung Cancer; Renal Cell Carcinoma; Hepatocellular Carcinomarecruiting170
2026-12 est.P2Lantern Pharma Inc. LTRNNCT05456256 A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaAdenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lungrecruiting90
2026-12 est.P1/P2AP Biosciences Inc.NCT05473156 A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion Locally Advanced or Metastatic Solid Tumors; Non Small Cell Lung Cancer (NSCLC); Head and Neck Squamrecruiting168
2026-12 est.P1/P2Jiangsu HengRui Medicine Co., Ltd.NCT05482568 A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung CancerAdvanced Non-small Cell Lung Cancerrecruiting324
2026-12 est.P1/P2Monte Rosa Therapeutics, Inc GLUENCT05546268 Study of Oral MRT-2359 in Selected Cancer PatientsNSCLC; SCLC; High Grade Neuroendocrine Cancer; DLBCL; L-MYC and N-MYC Amplified Solid Tumors; NSCLC active not recruiting174
2026-12 est.P3Mabscale, LLCNCT05654454 A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung CancerNon-Small Cell Lung Cancerrecruiting620
2026-12 est.P1/P2A2 Biotherapeutics Inc.NCT05736731 A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 ExpressionSolid Tumor, Adult; Solid Tumor; Pancreatic Cancer; Pancreatic Neoplasms; Pancreas Cancer; Non Smallactive not recruiting160
2026-12 est.P1/P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05949606 A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung CancerNon-small Cell Lung Canceractive not recruiting95
2026-12 est.P2Sichuan Baili Pharmaceutical Co., Ltd.NCT05956587 A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumNon-small Cell Lung Cancer; Nasopharyngeal Carcinomarecruiting121
2026-12 est.P1/P2Sichuan Baili Pharmaceutical Co., Ltd.NCT06114511 A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung CancerNon-small Cell Lung Canceractive not recruiting78
2026-12 est.P2Eikon Therapeutics EIKNNCT06246110 A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCNSCLCactive not recruiting70
2026-12 est.P3Sichuan Baili Pharmaceutical Co., Ltd.NCT06382129 A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)Non-small Cell Lung Canceractive not recruiting698
2026-12 est.P3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06671379 A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLCNon-small Cell Lung Canceractive not recruiting498
2026-12 est.P3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT06711900 A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients WiNon-Small Cell Lung Canceractive not recruiting432
2026-12 est.P3Qilu Pharmaceutical Co., Ltd.NCT06754644 A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLCNSCLCrecruiting808
2026-12 est.P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06844474 A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLCNSCLCrecruiting300
2026-12 est.P1/P2AkesoNCT06943820 AK129 Combination Therapy for Advanced Solid TumorsNon-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal recruiting230
2026-12 est.P1/P2One-carbon Therapeutics ABNCT07151040 Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid TumorsSolid Tumor; Colorectal Cancer (CRC); Squamous Cell Carcinoma of Head and Neck; Non-Small Cell Lung recruiting43
2026-12-01 est.P2Beijing Biostar Pharmaceuticals Co., Ltd.NCT06683703 Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain MetastasesNon-small Cell Lung Cancer Patients with Brain Metastasesnot yet recruiting118
2026-12-10 est.P3Boehringer IngelheimNCT06151574 Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With StandarLung Cancer, Non-squamous, Non-small Cellactive not recruiting428
2026-12-12 est.P3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07376382 A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLCNSCLCnot yet recruiting680
2026-12-14 est.P3Amgen AMGNNCT06430866 Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)active not recruiting163
2026-12-15 est.P1/P2PMV Pharmaceuticals, Inc PMVPNCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung Crecruiting300
2026-12-15 est.P1/P2GV20 TherapeuticsNCT05669430 A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesSolid Tumor, Adult; Refractory Cancer; Endometrial Carcinoma (EC); Squamous Head and Neck Carcinoma;recruiting365
2026-12-25 est.P2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06525350 A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel(Albumin Bound)Verse Docetaxel for the Treatment of MET-overexpressed Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpressionot yet recruiting256
2026-12-30 est.P1/P2Astellas Pharma Global Development, Inc.NCT06792435 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.Pancreatic Adenocarcinoma Metastatic; Lung Cancer (NSCLC); Ovarian Cancer; Colorectal Cancer Metastaactive not recruiting240
2026-12-30 est.P2HC Biopharma Inc.NCT07169552 HC010 in First-line PD-L1 Positive Advanced NSCLC PatientsNSCLCrecruiting50
2026-12-31 est.P2Partner Therapeutics, Inc.NCT02912949 A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)Solid Tumours Harboring NRG1 Fusion; NSCLC Harboring NRG1 Fusion; Pancreatic Cancer Harboring NRG1 Factive not recruiting250
2026-12-31 est.P1/P2BicycleTx LimitedNCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionAdvanced Solid Tumor Historically Known for High EphA2 Expression; Urothelial Cancer; Ovarian Canceractive not recruiting288
2026-12-31 est.P3Pfizer PFENCT05059522 Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingAdvanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumorsactive not recruiting77
2026-12-31 est.P1/P2Avistone Biotechnology Co., Ltd.NCT06343064 Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKINon-Small-Cell Lung Cancerrecruiting156
2026-12-31 est.P2Jazz Pharmaceuticals JAZZNCT06695845 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsBreast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endomerecruiting200
2026-12-31 est.P3Qilu Pharmaceutical Co., Ltd.NCT07162883 Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small-Cell Lungactive not recruiting146
2026-12-31 est.P2Innovent Biologics (Suzhou) Co. Ltd.NCT07402070 IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung CancerResectable Stage II-III Non-small Cell Lung Cancernot yet recruiting10
2027-01 est.P1/P2BicycleTx LimitedNCT04561362 Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced MalignanciesUrinary Bladder Neoplasm; Triple Negative Breast Neoplasms; Hormone Receptor Positive, HER2-negativeactive not recruiting329
2027-01 est.P1/P2iOncturaNCT06879717 A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) PatientsNon-Squamous Non-Small Cell Lung Cancer (NSCLC); Advanced Non Squamous NSCLCactive not recruiting45
2027-01-01 est.P1/P2Second Life TherapeuticsNCT07341737 SL-28 for Advanced Solid TumoursHead & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cancerecruiting60
2027-01-08 est.P3AstraZeneca AZNNCT05221840 A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Non-Small Cell Lung Canceractive not recruiting1051
2027-01-11 est.P3AstraZeneca AZNNCT06417814 A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGMetastatic Non-small Cell Lung Canceractive not recruiting768
2027-01-12 est.P3Merck Sharp & Dohme LLC MRKNCT05609968 Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell LungCarcinoma, Non-Small-Cell Lungactive not recruiting614
2027-01-19 est.P3Hoffmann-La RocheNCT05170204 A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung CNon-Small Cell Lung Canceractive not recruiting68
2027-01-25 est.P1/P2Novartis Pharmaceuticals NVSNCT04699188 Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationKRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small-Cell Lung; Carcinoma, Colorectal; Cancer of Lungactive not recruiting344
2027-01-31 est.P1/P2Janssen Research & Development, LLCNCT05908734 A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung CancerCarcinoma, Non-Small-Cell Lungactive not recruiting71
2027-02 est.P1/P2Krystal Biotech, Inc. KRYSNCT06228326 A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the LungsLung Cancer, Non-small Cell; Lung Cancer Metastatic; Solid Tumor, Adult; Advanced Cancer; Lung Cancerecruiting250
2027-02 est.P2Genelux Corporation GNLXNCT06463665 Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerAdvanced Non-squamous Non-small-cell Lung Cancer; Advanced Squamous Non-Small Cell Lung Carcinoma; Mrecruiting142
2027-02 est.P1/P2GI Innovation, Inc.NCT07172802 A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid TumorsAdvanced Solid Tumor; Metastatic Solid Tumor; Non-small Cell Lung Cancer (NSCLC); Head and Neck (HNSrecruiting102
2027-02-05 est.P2Bristol-Myers Squibb BMYNCT06946797 A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously UnNon-Small Cell Lung Canceractive not recruiting76
2027-02-14 est.P1/P2Beijing BiotechNCT07467863 Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLCNon-Small Cell Lung Cancer; Advanced/Metastatic NSCLCrecruiting48
2027-02-16 est.P3Bristol-Myers Squibb BMYNCT06140836 A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small CelCarcinoma, Non-Small-Cell Lungactive not recruiting190

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-18 est.P2ToLymph Inc.NCT06693336 An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell Lung Cancer (NSCLC)recruiting42
2026-11-18 est.P2/P3Medicine Invention Design, IncNCT05987956 Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide PolymorphismsALK-Positive Non-Small Cell Lung Cancer (NSCLC)active not recruiting600
2026-11 est.P2Avistone Biotechnology Co., Ltd.NCT07336732 Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR MutationsNon-Small-Cell Lung Cancerrecruiting40
2026-11 est.P3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT06448312 A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNon-Small Cell Lung Canceractive not recruiting406
2026-11 est.P2MediLink Therapeutics (Suzhou) Co., Ltd.NCT06107686 A Study of YL202 in Selected Patients With Advanced Solid TumorsNSCLC; Breast Cancer; HNSCC; Locally Advanced or Metastatic Solid Tumorsrecruiting200
2026-10-31 est.P2Amgen AMGNNCT06593522 A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)MTAP-deleted NSCLCactive not recruiting61
2026-10-31 est.P2Avistone Biotechnology Co., Ltd.NCT06574347 Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.Non-Small-Cell Lung Cancerrecruiting120
2026-10-29P2Hoffmann-La RocheNCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (FusioBreast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell,completed534
2026-10-28 est.P3AkesoNCT06617416 A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLCNSCLC (Non-small Cell Lung Cancer)recruiting560
2026-10-27 est.P2AstraZeneca AZNNCT06008093 A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With ChemotherapCarcinoma, Non-Small-Cell Lungactive not recruiting103
2026-10-26P2GlaxoSmithKlineNCT05565378 A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerLung Cancer, Non-Small Cellactive not recruiting351
2026-10-06P3ArriVent BioPharma, Inc. AVBPNCT05607550 Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With EpidermalMetastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; EGFR Exon 20 Mutationsactive not recruiting398
2026-10-01 est.P1/P2Inhatarget TherapeuticsNCT06896890 Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung CancerNSCLC (advanced Non-small Cell Lung Cancer); Stage IV Lung Cancerrecruiting32
2026-10-01P1/P2Merus B.V.NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in CombinationNon-Small Cell Lung Cancer Metastatic; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Head and terminated194
2026-10 est.P2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT07229729 A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung CancerNon-small Cell Lung Cancerrecruiting300
2026-10 est.P1/P2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06512051 A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung CancerAdvanced or Metastatic Non-small Cell Lung Cancerrecruiting248
2026-09-30 est.P2Innovent Biologics (Suzhou) Co. Ltd.NCT07124793 A Study of IBI363 Combination Therapy in Participants With Advanced Solid TumorsEGFR Mutant NSCLC and Platinum Resistant Ovarian Cancernot yet recruiting60
2026-09-30 est.P3Shanghai JMT-Bio Inc.NCT06735391 A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic NonLocally Advanced or Metastatic Non-squamous NSCLC; Harboring EGFR Sensitive Mutations NSCLC; Previourecruiting516
2026-09-30 est.P3Beijing Pearl Biotechnology Limited Liability CompanyNCT05989542 A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)Non-small Cell Lung Cancerrecruiting136
2026-09-30 est.P2Mirati Therapeutics Inc.NCT05609578 Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationAdvanced NSCLC; Metastatic Lung Canceractive not recruiting90
2026-09-30 est.P1/P2J Ints BioNCT05394831 A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLCEGFR Mutant Advanced Non-small Cell Lung Cancerrecruiting150
2026-09-30 est.P3Innovent Biologics (Suzhou) Co. Ltd.NCT05116462 Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung CancerNon-Small Cell Lung Canceractive not recruiting506
2026-09-30 est.P3Hoffmann-La RocheNCT04603807 A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) WitCarcinoma, Non-Small-Cell Lungactive not recruiting217
2026-09-29P1/P2Takeda TAKNCT02716116 A Study of TAK-788 in Adults With Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell Lungcompleted324
2026-09-28P1/P2Novartis Pharmaceuticals NVSNCT05358249 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationKRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-Sterminated74
2026-09-22 est.P1/P2ImmVira Pharma Co. LtdNCT04370587 A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or MeSolid Tumor; Melanoma; HNSCC; Sarcoma; Squamous Cell Carcinoma; NSCLCrecruiting30
2026-09-22P3Takeda TAKNCT04129502 TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsAdvanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)completed354
2026-09-15 est.P1/P2Wuhan YZY Biopharma Co., Ltd.NCT05543330 A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLCMalignant Pleural Effusions; NSCLC Stage IVrecruiting116
2026-09-03P3Novartis Pharmaceuticals NVSNCT05132075 Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung CancerNon-Small Cell Lung Cancerterminated95
2026-08-31 est.P2Shenyang Sunshine Pharmaceutical Co., LTD.NCT07171606 A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) PatientsFirst-line Advanced NSCLC Patientsrecruiting240
2026-08-31P2Klus Pharma Inc.NCT05816252 A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)Non-small Cell Lung Canceractive not recruiting356
2026-08-24 est.P2Regeneron Pharmaceuticals REGNNCT06161441 A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in AResectable Non-small Cell Lung Canceractive not recruiting195
2026-08-17P3AstraZeneca AZNNCT05984277 A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.Metastatic Non-small Cell Lung Canceractive not recruiting895
2026-08-10P3AstraZeneca AZNNCT05211895 A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCNon-Small Cell Lung Canceractive not recruiting791
2026-08-01 est.P1/P2OncoResponse, Inc.NCT06090266 A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer AgentsCancer; Tumor, Solid; Malignant Neoplasm; Metastatic Cancer; Advanced Solid Tumor; Cutaneous Melanomrecruiting168
2026-08-01 est.P1/P2Bridge Biotherapeutics, Inc.NCT05920135 First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKIEGFR Mutant Advanced Non-Small Cell Lung Canceractive not recruiting24
2026-08 est.P2Tasly Biopharmaceuticals Co., Ltd.NCT06724263 A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid TumorsRecurrent Platinum-resistant Epithelial Ovarian Cancer; Triple Negative Breast Cancer (TNBC); Cervicnot yet recruiting120
2026-08 est.P3Yantai LNC Biotechnology Singapore PTE. LTD.NCT06416852 Clinical Study of 18F-Alfatide Injection PET/CTNon-Small Cell Lung Cancer NSCLCnot yet recruiting428
2026-08 est.P3Sichuan Baili Pharmaceutical Co., Ltd.NCT06382116 A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)Non-small Cell Lung Canceractive not recruiting432
2026-08 est.P2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT05351788 SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.Non-small Cell Lung Cancerrecruiting110
2026-08 est.P1/P2Allist Pharmaceuticals, Inc.NCT05009329 A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in ChinaNSCLC; Solid Tumoractive not recruiting315
2026-07-31P3Hoffmann-La RocheNCT06624059 A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung Cancercompleted11
2026-07-30 est.P3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT06927986 Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC(SYNSTAR01)EGFR-mutated Locally Advanced or Metastatic NSCLCrecruiting380
2026-07-28 est.P1/P2Lantern Pharma Inc. LTRNNCT05933265 Study of LP-184 in Patients With Advanced Solid TumorsAdvanced Solid Tumor; Metastatic Solid Tumor; GBM; TNBC - Triple-Negative Breast Cancer; NSCLC; Pancactive not recruiting64
2026-07-15P1/P2EMD Serono Research & Development Institute, Inc.NCT05882734 Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)Non-Small Cell Lung Cancercompleted61
2026-07-13P1/P2GlaxoSmithKlineNCT06405230 Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker PositroLung Cancer, Non-Small Cellterminated2
2026-07-10P3AstraZeneca AZNNCT06564844 A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete TuNon-small Cell Lung Canceractive not recruiting25
2026-07-06P3AstraZeneca AZNNCT05261399 Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatCarcinoma; Non-Small-Cell Lungactive not recruiting341
2026-07-01 est.P2/P3Shanghai JMT-Bio Inc.NCT06319313 Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung CancerSquamous Cell Non-small Cell Lung Cancernot yet recruiting534
2026-07 est.P3Sichuan Baili Pharmaceutical Co., Ltd.NCT05943795 A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell CarcinomaNon-small Cell Lung Adenocarcinoma; Squamous Cell Carcinoma of Lungactive not recruiting589
2026-07 est.P1/P2CJ Bioscience, Inc.NCT05877430 Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic CancerNSCLC; HNSCC; Melanoma; Metastatic Cancer; Advanced Solid Tumor; Advanced Cancerrecruiting160
2026-07 est.P2AkesoNCT04736823 A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLCNSCLCactive not recruiting265
2026-07 est.P2AbbVie ABBVNCT03539536 Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerNon-small Cell Lung Canceractive not recruiting270
2026-06-30 est.P1/P2Suzhou Puhe Pharmaceutical Technology Co., LTDNCT06590194 PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)unknown96
2026-06-30P3GlaxoSmithKlineNCT06472076 A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) HigLung Cancer, Non-Small Cellactive not recruiting88
2026-06-30 est.P1/P2AkesoNCT05904379 AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung CancerAdvanced Non-small-cell Lung Canceractive not recruiting233
2026-06-30 est.P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT05416775 Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung CancerAdvanced Non-small Cell Lung Cancerunknown168
2026-06-15P3Merck Sharp & Dohme LLC MRKNCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent ChemoraCarcinoma, Non-Small-Cell Lungcompleted610
2026-06-09P3AstraZeneca AZNNCT05048797 A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small CLocally Advanced or Metastatic Non-Small Cell Lung Canceractive not recruiting454
2026-06-08P2Dizal PharmaceuticalsNCT06295432 A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)Non-small Cell Lung Cancercompleted30
2026-06-01 est.P2/P3Hansoh BioMedical R&D CompanyNCT06417008 A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung CancerNon-Squamous Non-Small Cell Lung Cancerrecruiting1080
2026-06 est.P2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06496490 A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene AbnormalityNon-Small Cell Lung Cancerrecruiting270
2026-06 est.P1/P2Volastra Therapeutics, Inc.NCT05902988 A Phase I/II Study of VLS-1488 in Subjects With Advanced CancerAdvanced Solid Tumor; High Grade Serous Adenocarcinoma of Ovary; Squamous Non-small-cell Lung Cancerrecruiting200
2026-05-31 est.P2RemeGen Co., Ltd.NCT06962865 A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or RNon-Small Cell Lung Cancerrecruiting80

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "non-small cell lung cancer"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.